Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AFLAC Incorporated (AFL) vs Mesoblast Limited (MESO) Price & Performance

AFLAC IncorporatedTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

AFLAC Incorporated vs Mesoblast Limited — how do they compare? AFLAC Incorporated trades at $121.06 (market cap $61.13B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: AFLAC Incorporated is far larger — about 28.3× Mesoblast Limited's market cap, and AFLAC Incorporated pays a 2% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

AFLMESO
Market Cap
$61.13B$2.16B
Sector
FinancialsTechnology
52-Week High
$129.55$20.96
52-Week Low
$103.55$12.88
Enterprise Value
$71.08B$2.17B
Dividend Yield
2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AFLAC Incorporated

No Aura AI signal available yet.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AFLAC Incorporated

Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.

Read more on AFL

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO